Table 1.

Overall characteristics of 16 breast cancer patients undergoing NAC

Patient	TNM	ER status	PR status	HER2/neu	NAC regimen	Adjuvant regimen
1	T2N0M0	Negative	Negative	Negative	Doxorubicin, cyclophosphamide and docetaxel	Tamoxifen plus radiation
2	T3N1M0	Strongly positive	Negative	Strongly positive	Doxorubicin, cyclophosphamide and docetaxel	Tamoxifen plus radiation
3	T2N0M0	Strongly positive	Strongly positive	Negative	Vinorelbine and docetaxel	Tamoxifen; paclitaxel; fulvestrant & palbociclib
4	T2N1M0	Strongly positive	Weakly positive	Negative	Vinorelbine and docetaxel	Doxorubicin, cyclophosphamide & tamoxifen; exemestane; gem-citabine
5	T2N1M0	Negative	Negative	Strongly positive	Vinorelbine, docetaxel and trastuzumab	None
6	T2N0M0	Strongly positive	Strongly positive	Strongly positive	Paclitaxel	Tamoxifen
7	T3N1M0	Negative	Negative	Strongly positive	Vinorelbine, docetaxel and trastuzumab	Doxorubicin & cyclophosphamide plus radiation
8	T3N1M0	Negative	Negative	Strongly positive	Docetaxel and trastuzumab	Capecitabine plus radiation
9	T3N2M0	Negative	Negative	Negative	Doxorubicin and cyclophosphamide	Docetaxel; gem-citabine & bryostatin; capecitabine plus radiation
10	T3N2M0	Negative	Negative	Strongly positive	Doxorubicin, cyclophosphamide and docetaxel	Capecitabine plus radiation
11	T3N0M0	Negative	Negative	Negative	Doxorubicin, cyclophosphamide & docetaxel	Radiation
12	T2N1M0	Strongly positive	Strongly positive	Negative	Doxorubicin and cyclophosphamide	Docetaxel
13	T3N1M0	Strongly positive	Weakly positive	Negative	Doxorubicin and cyclophosphamide	Radiation; tamoxifen
14	T3N2M0	Strongly positive	Strongly positive	Negative	Doxorubicin and docetaxel	Cyclophosphamide, cisplatin & carmustine
15	T4N1M0	Negative	Negative	Negative	Doxorubicin and docetaxel	None
16	Staging not complete	Weakly positive	Negative	Weakly positive	Doxorubicin, docetaxel and 5-FU	None